Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02014844
Recruitment Status : Completed
First Posted : December 18, 2013
Last Update Posted : February 10, 2022
Information provided by (Responsible Party):
ImmunityBio, Inc.

Brief Summary:
This is a pilot study to determine the efficacy and safety of aldoxorubicin in subjects with glioblastoma who have progressed following surgery and prior treatments.

Condition or disease Intervention/treatment Phase
Glioblastoma Drug: aldoxorubicin Phase 2

Detailed Description:
This is a second line open-labeled pilot phase 2 study in subjects with glioblastoma whose tumors have progressed following prior treatment with surgery, radiation and Temozolomide. Patients who have received avastin as a second-line treatment are not eligible for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 28 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of Aldoxorubicin in Subjects With Unresectable Glioblastoma Whose Tumors Have Progressed Following Prior Treatment With Surgery, Radiation and Temozolomide
Study Start Date : March 2014
Actual Primary Completion Date : December 2016
Actual Study Completion Date : December 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Safety

Arm Intervention/treatment
Experimental: aldoxorubicin
Subjects will receive either 250 mg/m2 or 350 mg/m2 aldoxorubicin IV.
Drug: aldoxorubicin
Other Name: INNO-206

Primary Outcome Measures :
  1. Objective Response Rate (Complete Response and Partial Response) [ Time Frame: up to 6 months ]
    The study will measure the complete response and partial response rate in these subjects using the RANO Working Group Criteria.

Secondary Outcome Measures :
  1. Safety [ Time Frame: up to 6 months ]
    The secondary objectives of this study are to evaluate the safety of aldoxorubicin in this population assessed by the frequency and severity of adverse events (AEs, abnormal findings on physical examination, laboratory tests, vital signs, echocardiogram evaluations, ECG results, weight, and the change in performance status as measured by the Karnofsky Performance Scale.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age 18 years or older; male or female
  2. Histologically or cytologically confirmed unresectable GBM. Subjects with recurrent disease whose prior pathology demonstrated GBM will not need to be re-biopsied. Subjects with prior low-grade glioma or anaplastic glioma are eligible if histological assessment demonstrates transformation into GBM.
  3. Cancer progression after treatment with the following: surgery, radiation therapy and temozolomide as first line treatment with no other therapy prior to tumor recurrence.

    1. Radiographic progression by RANO Working Group Criteria will be confirmed by Imaging Endpoints, a central imaging vendor.
    2. By tumor biopsy if conducted within 4 weeks of randomization.
  4. An interval of at least 12 weeks after last dose of radiation and temozolomide is required, unless cancer progression is proven by diagnostic tumor biopsy. If temozolomide is being used in a maintenance phase, there must be a 28-day washout period prior to Randomization.
  5. Stable or decreasing dose of corticosteroids for at least 7 days prior to randomization.
  6. Capable of providing informed consent and complying with trial procedures.
  7. Karnofsky Performance Status 70 or above.
  8. ECOG performance status 0-2.
  9. Life expectancy 8 or more weeks.
  10. Measurable tumor lesions according to RANO working Group Criteria.

    a. In the case that there is "non-measurable" disease due to a radical surgical resection during screening, the subject still qualifies if Inclusion #3(b) is met.

  11. Women must not be able to become pregnant for the duration of the study.
  12. Women of childbearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating.
  13. Geographically accessible to site, i.e. the ability to come to the study site for each scheduled appointment and evaluation.

Exclusion Criteria:

  1. Prior exposure to the an anthracycline.
  2. Any therapeutic regimen for treatment of recurrent tumor after first line treatment with surgery, radiation and temozolomide.
  3. Prior treatment with bevacizumab or an experimental anti-angiogenic agent.
  4. Palliative surgery and/or radiation treatment less than 4 weeks to randomization.
  5. Exposure to any investigational agent within 30 days of Randomization.
  6. History of other malignancies (except cured basal cell carcinoma, superficial bladder cancer or carcinoma in situ of the cervix) unless documented free of cancer for 3 or more years.
  7. Laboratory values: screening serum creatinine > 1.5xULN, ALT > 2.5xULN, total bilirubin > 1.5xULN, ANC < 1500/mm3, platelet concentrations < 100,000/mm3, absolute lymphocyte count < 1000/mm3, hematocrit level < 27% for females or < 30% for males, serum albumin ≤ 2.5 g/dL, PT/INR 1.5xULN or >3xULN on anticoagulant with no evidence of active bleeding.
  8. Evidence of CNS hemorrhage CTCAE ≥ grade 2 on baseline MRI.
  9. Clinically evident congestive heart failure > class II of the NYHA guidelines.
  10. Current, serious, clinically significant cardiac arrhythmias, defined as the existence of an absolute arrhythmia or ventricular arrythmias classified as Lown III, IV or V.
  11. History or signs of active coronary artery disease with or without angina pectoris.
  12. Serious myocardial dysfunction defined as ultrasound-determined LVEF < 45% of predicted institutional normal value.
  13. Baseline ATc>470 msec and/or previous history of QT prolongation.
  14. Active, clinically significant serious infection requiring treatment with antibiotics, anti-virals, or anti-fungals.
  15. History of HIV infection.
  16. Major surgery, except diagnostic tumor biopsy, within 4 weeks of randomization.
  17. Any condition that might interfere with the subject's participation in the study or in the evaluation of the study results.
  18. Any condition that is unstable and could jeopardize the subject's participation in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02014844

Layout table for location information
United States, California
City of Hope National Medical Center
Duarte, California, United States, 91010
Sarcoma Oncology Center
Santa Monica, California, United States, 90403
United States, Louisiana
Ochsner Health System
New Orleans, Louisiana, United States, 70115-6969
United States, Texas
Texas Oncology-Austin Midtown
Austin, Texas, United States, 78705
Sponsors and Collaborators
ImmunityBio, Inc.
Layout table for additonal information
Responsible Party: ImmunityBio, Inc. Identifier: NCT02014844    
Other Study ID Numbers: ALDOXORUBICIN-P2-GBM-01
First Posted: December 18, 2013    Key Record Dates
Last Update Posted: February 10, 2022
Last Verified: September 2015
Keywords provided by ImmunityBio, Inc.:
brain cancer
brain tumor
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue